To evaluate the role of a therapeutic regimen with plasma exchange, intravenous immunoglobulins and rituximab in chronic-active antibody-mediated rejection (cAMR) settings.

Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Mella, Alberto;Gallo, Ester;Messina, Maria;Caorsi, Cristiana;Amoroso, Antonio;Gontero, Paolo;Maletta, Francesca;Barreca, Antonella;Fop, Fabrizio;Biancone, Luigi
Last
2018-01-01

Abstract

To evaluate the role of a therapeutic regimen with plasma exchange, intravenous immunoglobulins and rituximab in chronic-active antibody-mediated rejection (cAMR) settings.
2018
8
5
178
187
https://www.wjgnet.com/2220-3230/full/v8/i5/178.htm
Chronic-active antibody-mediated rejection; Donor-specific antibody; Kidney transplantation; Rituximab
Mella, Alberto; Gallo, Ester; Messina, Maria; Caorsi, Cristiana; Amoroso, Antonio; Gontero, Paolo; Verri, Aldo; Maletta, Francesca; Barreca, Antonella; Fop, Fabrizio; Biancone, Luigi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1680516
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact